Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

We’re encouraged to drink more water because ‘it’s good for us.’ Now, a new study has tested that claim, examining the evidence from previous studies to see whether increasing the amount of water you ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Medical experts share their answers to all your questions on bladder problems, from urinary tract infections to odd urine ...

Many people believe that urinary tract infections (UTIs) and incontinence are more common in women, but they can also affect ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa (vibegron), a beta-3 (β3) adrenergic receptor agonist, dosed once-daily (75mg ...

Sumitomo Pharma’s oral treatment for overactive bladder symptoms has won an expanded label from the FDA, and is now approved ...

The therapeutic response rate was 79% at 24 months, which is comparable to the rates seen at 6 months (78%) and 12 months (82%).

Generally, there’s a certain number of times you should pee daily. Deviating too far from this can suggest various things about your health, experts say.